GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population

Months after GSK’s Nucala cleared in a pivotal rare blood disorder study, the asthma biologic has scored in a late-stage trial in chronic rhinosinusitis patients with nasal polyps.